Loading...
•
Sep 30
Aytu BioScience Q1 2026 Earnings Report
Aytu BioPharma posted net income in Q1 2026 and maintained solid cash reserves while preparing for the launch of EXXUA.
Key Takeaways
Aytu reported $13.9 million in revenue for Q1 FY2026, with net income of $2.0 million. The company is advancing toward a Q4 calendar 2025 commercial launch of EXXUA, a novel antidepressant. Despite adjusted EBITDA being negative due to launch investments, the company remains well-capitalized with over $32 million in cash.
Reported net revenue of $13.9 million, down year-over-year but up 5% excluding a one-time rebate in Q1 FY2025.
Achieved net income of $2.0 million, an increase from $1.5 million in the prior year quarter.
Adjusted EBITDA was -$0.6 million, reflecting investments in EXXUA's launch.
Maintained strong cash position with $32.6 million in cash and equivalents as of September 30, 2025.
Aytu BioScience
Aytu BioScience
Aytu BioScience Revenue by Segment
Revenue by Segment
ADHD Portfolio Revenue
CapyFin.comPediatric Portfolio Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Aytu plans to launch EXXUA in Q4 2025 and anticipates it will become a major growth catalyst in the MDD market.
Positive Outlook
- EXXUA commercial launch on track for Q4 2025
- Final product manufacturing and distribution processes underway
- Sales force training and promotional materials nearing completion
- Established pricing and patient support infrastructure in place
- Patent protection for EXXUA extended through September 2030
Challenges Ahead
- Adjusted EBITDA turned negative in the quarter
- Pediatric portfolio revenue declined due to manufacturing delays and product returns
- Overall revenue declined YoY due to prior year rebate benefit
- Operating loss of $1.5 million recorded
- Still dependent on successful EXXUA launch for near-term growth
Revenue & Expenses
Visualization of income flow from segment revenue to net income